Anthony C Bejjani

Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study

V. Koshkin, N. Housri, M. Karuturi, 2022, JMIR cancer.

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.

R. Finn, Anthony C Bejjani, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

V. Mazzaferro, P. Galle, J. Llovet, 2021, Gastroenterology.

Very Unstable Genetics: How the Confluence of Microsatellite Instability and Immunotherapy Revolutionized the Treatment of Colon Cancer

J. Kaunitz, Anthony C Bejjani, Anthony Bejjani, 2023, Digestive Diseases and Sciences.

Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma

R. Finn, Anthony C Bejjani, 2023, Surgical Oncology Clinics of North America.

Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic.

N. Housri, A. Bejjani, L. Burt, 2020, JCO clinical cancer informatics.

Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.

R. Finn, A. Bejjani, S. Sadeghi, 2019, Surgical oncology clinics of North America.

Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management

R. Finn, A. Bejjani, Anthony C Bejjani, 2018, Current Hepatology Reports.

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

V. Mazzaferro, P. Galle, J. Llovet, 2022, Gastroenterology.